MEN-10755

MEN-10755 is a pharmaceutical drug currently under development by the biopharmaceutical company Menarini. It is being investigated for its potential use in the treatment of pulmonary arterial hypertension (PAH), a rare and severe condition characterized by high blood pressure in the arteries of the lungs.

Overview

MEN-10755 is a dual endothelin receptor antagonist (ERA), meaning it blocks the action of endothelin, a potent vasoconstrictor peptide. By blocking the action of endothelin, MEN-10755 is expected to dilate the blood vessels in the lungs, reducing the pressure and improving the symptoms of PAH.

Development

The development of MEN-10755 is currently in the clinical trial phase. The drug has shown promising results in preclinical studies, demonstrating a potent and long-lasting effect in reducing pulmonary arterial pressure. The ongoing clinical trials aim to confirm these results in patients with PAH.

Potential Impact

If successful, MEN-10755 could provide a new treatment option for patients with PAH, a condition for which there is currently no cure. The drug could potentially improve the quality of life and survival rates for these patients.

See Also

• Pulmonary arterial hypertension
• Endothelin receptor antagonist
• Clinical trial
• Menarini